BEWARE: Big Pharma is Working on Covid-19/Flu Vaccine Cocktail Just in Time for FallAustin Roe
From “Will mRNA Flu Vaccines Get Emergency Use Authorization Next?” at Citizen Journal:
Analysis by Dr. Joseph Mercola
As detailed in “How COVID Vaccines Can Cause Blood Clots and More,” the gene-based COVID-19 injections are a disaster in the making. mRNA-based “vaccines” have been in the works for years, and were never perfected. Now all of a sudden, despite evidence of serious danger, a number of mRNA “vaccines” are in the pipeline.
Among them is a COVID-flu RNA vaccine combo, which is currently being tested on ferrets,1,2,3 and several different mRNA seasonal influenza vaccines,4 which have already entered human trials. As reported by The Verge, July 7, 2021:5
“Moderna gave its mRNA-based seasonal flu vaccine to the first set of volunteers in a clinical trial, the pharmaceutical company announced today. The start of the trial marks the next stage of the company’s work on this type of vaccine technology after the overwhelming success of its COVID-19 vaccine, which was built using the same strategy …
People who get an mRNA vaccine are injected with tiny snippets of genetic material from the target virus. Their cells use that genetic information to build bits of the virus, which the body’s immune system learns to fight against …
Moderna is the second group to start testing its mRNA flu shot in human trials — Sanofi and Translate Bio kicked off a trial this summer. Pfizer and BioNTech have been interested in mRNA flu shots for a few years, and they’re pushing forward with those plans as well.”
Moderna Tests Quadrivalent mRNA Flu ‘Vaccine’
Moderna plans to enroll 180 participants aged 18 and older in its Phase 1/2 randomized, stratified, observer-blind, dose-ranging6 study of mRNA-1010, a quadrivalent flu “vaccine” that aims to protect against seasonal influenza A H1N1, H3N2 and influenza B Yamagata and Victoria.
In a press release, Moderna’s CEO Stephanie Bancel stated the company hopes to be able to create combination vaccines to protect against several different infections at the same time, such as influenza, COVID-19 and other respiratory infections:7
“Respiratory combination vaccines are an important pillar of our overall mRNA vaccine strategy,” Bancel said. “We believe that the advantages of mRNA vaccines include the ability to combine different antigens to protect against multiple viruses and the ability to rapidly respond to the evolution of respiratory viruses, such as influenza, SARS-CoV-2 and RSV.
Our vision is to develop an mRNA combination vaccine so that people can get one shot each fall for high efficacy protection against the most problematic respiratory viruses.”
The rapid push to replace conventional flu vaccines with mRNA-based alternatives — before mRNA COVID shots have even been licensed — raises the question, and risk, of whether mRNA flu shots might be getting emergency use authorization (EUA) next.